IP Library › Granted Patent US 10,456,445
Granted Patent B2
US 10,456,445 · App. 15/314,970 · Granted Oct 29, 2019

Methods and compositions for immunomodulation

Inventors: David M. Briscoe (Sharon, MA); Michael Klagsbrun (Newton, MA); Sarah Bruneau (Boston, MA); Nora Kochupurakkal (Boston, MA); Hironao Nakayama (Boston, MA)
Assignee: CHILDREN'S MEDICAL CENTER CORPORATION
A61K38/1709A61K38/177A61K38/482A61K45/06C07K16/18C07K16/28C07K16/2803C12Y304/21C12Y304/21075A61K2039/505C07K2317/76
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,456,445
App. No.
15/314,970
Granted
Oct 29, 2019
Kind
B2
Abstract

The methods and uses described herein relate to the modulation of the immune system by modulation of Sema3F levels and/or activity, e.g. suppressing allograft rejection or inflammation by administering a Sema3F agonist or increasing an immune response by administering a Sema3F inhibitor.

Claims (32)

1. A method of suppressing allograft rejection, the method comprising administering a therapeutically effective amount of a Semaphorin 3F (Sema3F) agonist to an allograft recipient, whereby immune rejection of the allograft is suppressed, and

a. wherein the Sema3F agonist is a Sema3F polypeptide that binds to a Sema3F receptor, or

b. wherein the Sema3F agonist is a nucleic acid encoding a Sema3F polypeptide that binds to a Sema3F receptor.

2. The method of claim 1 , wherein the Sema3F agonist is a Sema3F polypeptide.

3. The method of claim 2 , wherein the polypeptide comprises a sequence having at least 95% identity to the sequence of SEQ ID NO: 1 or 5.

4. The method of claim 2 , wherein the Sema3F polypeptide comprises the sequence of SEQ ID NO: 5.

5. The method of claim 1 , wherein the Sema3F agonist is a nucleic acid encoding a Sema3F polypeptide.

6. The method of claim 1 , wherein the allograft is a cardiac allograft.

7. A method of prolonging the survival of an allogeneic transplant recipient, the method comprising administering a therapeutically effective amount of a Semaphorin 3F (Sema3F) agonist to an allogeneic transplant recipient, whereby the survival of the recipient is prolonged, and

a. wherein the Sema3F agonist is a Sema3F polypeptide that binds to a Sema3F receptor, or

b. wherein the Sema3F agonist is a nucleic acid encoding a Sema3F polypeptide that binds to a Sema3F receptor.

8. The method of claim 7 , wherein the Sema3F agonist is a Sema3F polypeptide.

9. The method of claim 8 , wherein the polypeptide comprises a sequence having at least 95% identity to the sequence of SEQ ID NO: 1 or 5.

10. The method of claim 8 , wherein the Sema3F polypeptide comprises the sequence of SEQ ID NO: 5.

11. The method of claim 7 , wherein the Sema3F agonist is a nucleic acid encoding a Sema3F polypeptide.

12. The method of claim 7 , wherein the allogeneic transplant is a cardiac allogeneic transplant.

13. A method of inhibiting rejection of an allogeneic transplant recipient, the method comprising administering a therapeutically effective amount of a Semaphorin 3F (Sema3F) agonist to an allogeneic transplant recipient, whereby rejection of the allogeneic transplant is inhibited, and

a. wherein the Sema3F agonist is a Sema3F polypeptide that binds to a Sema3F receptor, or

b. wherein the Sema3F agonist is a nucleic acid encoding a Sema3F polypeptide that binds to a Sema3F receptor.

14. The method of claim 13 , wherein the Sema3F agonist is a Sema3F polypeptide.

15. The method of claim 14 , wherein the polypeptide comprises a sequence having at least 95% identity to the sequence of SEQ ID NO: 1 or 5.

16. The method of claim 14 , wherein the Sema3F polypeptide comprises the sequence of SEQ ID NO: 5.

17. The method of claim 13 , wherein the Sema3F agonist is a nucleic acid encoding a Sema3F polypeptide.

18. The method of claim 13 , wherein the allogeneic transplant is a cardiac allogeneic transplant.

19. A method of inhibiting rejection of an organ transplant, the method comprising administering a therapeutically effective amount of a Semaphorin 3F (Sema3F) agonist to an organ transplant recipient, whereby rejection of the organ transplant is inhibited, and

a. wherein the Sema3F agonist is a Sema3F polypeptide that binds to a Sema3F receptor, or

b. wherein the Sema3F agonist is a nucleic acid encoding a Sema3F polypeptide that binds to a Sema3F receptor.

20. The method of claim 19 , wherein the Sema3F agonist is a Sema3F polypeptide.

21. The method of claim 20 , wherein the polypeptide comprises a sequence having at least 95% identity to the sequence of SEQ ID NO: 1 or 5.

22. The method of claim 20 , wherein the Sema3F polypeptide comprises the sequence of SEQ ID NO: 5.

23. The method of claim 19 , wherein the Sema3F agonist is a nucleic acid encoding a Sema3F polypeptide.

24. The method of claim 19 , wherein the organ transplant is a cardiac organ transplant.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 21, 2018
From: BRISCOE, DAVID M.; KOCHUPURAKKAL, NORA; KLAGSBRUN, MICHAEL; NAKAYAMA, HIRONAO; BRUNEAU, SARAH
To: CHILDREN'S MEDICAL CENTER CORPORATION
Reel/Frame 044986/0475 →
CONFIRMATORY LICENSE Recorded Apr 6, 2017
From: BOSTON CHILDREN'S HOSPITAL
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 042174/0699 →
Continuity (2)
Provisional Application 62006441 · Jun 2, 2014
Related Publication 20170100456A1 · Apr 13, 2017